文献速递肿瘤 PET/CT

Biograph Vision PET/CT系统图像质量与半定量测量的初步经验及与Biograph mCT的比较

Image Quality and Semiquantitative Measurements on the Biograph Vision PET/CT System: Initial Experiences and Comparison with the Biograph mCT.
PubMed 文献 · J Nucl Med · 2019-06-28

该研究纳入20例肿瘤患者,单次注射3 MBq/kg 18F-FDG后行双成像PET扫描,比较Biograph Vision与Biograph mCT的图像质量和半定量分析。结果显示Vision在肿瘤病灶边界、整体图像质量和图像噪声方面评分显著更高(P < 0.001),两系统在肿瘤病灶和健康组织的SUV agree良好(within 95%),尤其使用EARL兼容重建时。

要点

  • Biograph Vision在病灶边界、整体图像质量和图像噪声方面显著优于Biograph mCT(P < 0.001)。
  • 两系统在肿瘤病灶和健康组织的SUV agree良好(within 95%),尤其EARL兼容重建时。
  • 临床优化重建设置可能进一步提升定量性能。

核心结论

  • Biograph Vision在病灶边界、整体图像质量和视觉评估的信噪比方面较Biograph mCT图像质量改善。
  • 两系统在健康组织和肿瘤病灶的半定量图像生物标志物方面具有可比性。
  • 使用临床优化重建设置可能实现更好的定量性能。

研究设计与样本

  • 2018年5月Biograph Vision PET/CT系统安装于格罗宁根大学医学中心,本研究评估其初步经验并与Biograph mCT作为参考进行比较。
  • 共纳入20例肿瘤患者,单次注射3 MBq/kg 18F-FDG后行双成像PET扫描。
  • 10例患者先在Biograph mCT扫描,另10例先在Biograph Vision扫描。
  • 局部偏好的临床重建图像由3名核医学医师盲法审阅,采用Likert 1-5量表对肿瘤病灶边界、整体图像质量和图像噪声评分。
  • 临床重建图像用于测量肿瘤病灶SUV进行半定量分析;符合EARL规范的图像也用于测量肿瘤病灶和健康组织SUV以比较两系统。

主要发现

  • 14名男性和6名女性(年龄范围36-84岁;均值±标准差61±16岁)接受的18F-FDG剂量范围为145-405 MBq(均值±标准差268±59.3)。
  • Biograph Vision图像在肿瘤病灶边界、整体图像质量和图像噪声评分上显著高于Biograph mCT(P < 0.001)。
  • 总体读者间一致性Fleiss κ为0.61(95%置信区间0.53-0.70)。
  • 肿瘤病灶和健康组织的SUV在两PET/CT系统间agree良好(within 95%),尤其当两系统均使用EARL兼容重建时。

临床怎么用

  • 在临床工作中,Biograph Vision可提供更优的图像质量,有助于肿瘤病灶边界的识别和整体图像判读。
  • 两系统半定量SUV结果具有可比性,尤其在使用EARL兼容重建时,支持跨系统定量比较。
  • 临床优化重建设置可能进一步改善定量性能,值得在临床实践中关注。

局限性

  • 本研究为初步经验,样本量较小(20例肿瘤患者)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In May 2018, the Biograph Vision PET/CT system was installed at the University Medical Center Groningen. This study evaluated the initial experiences with this new PET/CT system in terms of perceived image quality and semiquantitative analysis in comparison to the Biograph mCT as a reference. Methods: In total, 20 oncologic patients were enrolled and received a single 3 MBq/kg injected dose of 18F-FDG followed by a dual-imaging PET scan. Ten patients were scanned on the Biograph mCT first, whereas the other 10 patients were scanned on the Biograph Vision first. The locally preferred clinically reconstructed images were blindly reviewed by 3 nuclear medicine physicians and scored (using a Likert scale of 1-5) on tumor lesion demarcation, overall image quality, and image noise. In addition, these clinically reconstructed images were used for semiquantitative analysis by measurement of SUVs in tumor lesions. Images acquired using reconstructions conform with the European Association of Nuclear Medicine Research Ltd. (EARL) specifications were also used for measurements of SUV in tumor lesions and healthy tissues for comparison between systems. Results: The 18F-FDG dose received by the 14 men and 6 women (age range, 36-84; mean ± SD, 61 ± 16 y) ranged from 145 to 405 MBq (mean ± SD, 268 ± 59.3). Images acquired on the Biograph Vision were scored significantly higher on tumor lesion demarcation, overall image quality, and image noise than images acquired on the Biograph mCT (P < 0.001). The overall interreader agreement showed a Fleiss κ of 0.61 (95% confidence interval, 0.53-0.70). Furthermore, the SUVs in tumor lesions and healthy tissues agreed well (within 95%) between PET/CT systems, particularly when EARL-compliant reconstructions were used on both systems. Conclusion: In this initial study, the Biograph Vision showed improved image quality compared with the Biograph mCT in terms of lesion demarcation, overall image quality, and visually assessed signal-to-noise ratio. The 2 systems are comparable in semiquantitatively assessed image biomarkers in both healthy tissues and tumor lesions. Improved quantitative performance may, however, be feasible using the clinically optimized reconstruction settings.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. van Sluis J, Boellaard R, Somasundaram A, et al. Image Quality and Semiquantitative Measurements on the Biograph Vision PET/CT System: Initial Experiences and Comparison with the Biograph mCT. J Nucl Med. 2019. PMID: 31253742. doi:10.2967/jnumed.119.227801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。